Knowledge Base for Nuclear Receptor Drug Discovery

Therapeutic Targets: Modulation, Inhibition, and Activation

Volumn , Issue , 2012, Pages 309-326

  Antolín, Albert A ^a   Mestres, Jordi ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Chemical knowledge base; Knowledge base in nuclear receptor drug discovery; Knowledge base, and interaction data between small molecules; Nuclear receptors, transcription factors regulating biological processes; Structural knowledge base

Indexed keywords

EID: 84887236585     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118185537.ch8     Document Type: Chapter

References (37)

1. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3:950-964 (2004).
2. Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Annu Rev Physiol 65:261-311 (2003).
3. Shi Y. Orphan nuclear receptors in drug discovery. Drug Discov Today 12:440-445 (2007).
4. Tenbaum S, Baniahmad A. Nuclear receptors: Structure, function and involvement in disease. Int J Biochem Cell Biol 29:1325-1341 (1997).
5. Nuclear Receptors Nomenclature Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell 97:161-163 (1999).
6. Germain P, Staels B, Dacquet C, Spedding M, Laudet V. Overview of nomenclature of nuclear receptors. Pharmacol Rev 58:685-704 (2006).
7. O'Malley B. The year in basic science: Nuclear receptors and corregulators. Mol Endocrinol 22:2751-2758 (2008).
8. Bridgham JT, Eick GN, Larroux C, Deshpande K, Harms MJ, Gauthier ME, Ortlund EA, Degnan BM, Thornton JW. Protein evolution by molecular tinkering: Diversification of the nuclear receptor superfamily from a ligand-dependent ancestor. PLoS Biol 8:e1000497 (2010).
9. Chen T. Nuclear receptor drug discovery. Curr Opin Chem Biol 12:418-426 (2008).
10. Moore JT, Collins JL, Pearce KH. The nuclear receptor superfamily and drug discovery. ChemMedChem 1:504-523 (2006).
11. Gregori-Puigjané E, Mestres J. Designing chemical libraries directed to nuclear receptors. In Ottow E, Weinmann H, eds. Nuclear Receptors as Drug Targets. Wiley-VCH, Weinheim, 2008, pp. 469-488.
12. Gleeson MP, Hersey A, Montanari D, Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov 10, 197-208 (2011) (available at http://www.ebi.ac.uk/chembldb/).
13. Jensen NH, Roth BL. Massively parallel screening of the receptorome. Comb Chem High- Throughput Screen 11:420-427 (2008). [Ki determinations were generously provided by the National Institute of Mental Health's Psychoactive Drug Screening Program, Contract HHSN-271-2008-00025-C (available at http://pdsp.med.unc.edu)].
14. Harmar AJ, Hills RA, Rosser EM, Jones M, Buneman OP, Dunbar DR, et al. IUPHARDB: The IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Res 37:D680-D685 (2009) (available at http://www.iuphar-db.org).
15. Wang Y, Bolton E, Dracheva S, Karapetyan K, Shoemaker BA, Suzek TO, et al. An overview of the PubChem bioassay resource. Nucleic Acids Res 38:D255-D266 (2010) (available at http://pubchem.ncbi.nlm.nih.gov).
16. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: A knowledge base for drugs, drug actions and drug targets. Nucleic Acids Res 36:D901- D906 (2008) (available at http://www.drugbank.ca).
17. Liu T, Lin Y, Wen X, Jorrisen RN, Gilson MK. BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35: D198-D201 (2007) (available at http://www.bindingdb.org).
18. Benson ML, Smith RD, Khazanov NA, Dimcheff B, Beaver J, Dresslar P, et al. Binding MOAD, a high-quality protein-ligand database. Nucleic Acids Res 36:D674-D678 (2008) (available at http://www.bindingmoad.org).
19. BlockP,SotrifferCA,DramburgI,KlebeG.AffinDB:Afreelyaccessibledatabaseof affinities for protein-ligand complexes from the PDB. Nucleic Acids Res 34:D522-D526 (2006) (available at http://pc1664.pharmazie.uni-marburg.de/affinity/).
20. Cases M, Garciá-Serna R, Hettne K, Weeber M, van der Lei J, Boyer S, Mestres J. Chemical and biological profiling of an annotated compound library directed to the nuclear receptor family. Curr Top Med Chem 5:763-772 (2005).
21. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res 28:235-242 (2000) (available at http://www.rcsb.org/).
22. Garciá-Serna R, Opatowski L, Mestres J. FCP: Functional coverage of the proteome by structures. Bioinformatics 22:1792-1793 (2006) (available at http://cgl.imim.es/fcp/).
23. Queralt-Rosinach N, Mestres J. A canonical cation-p interaction stabilizes the agonist conformation of estrogen-like nuclear receptors. Eur Biophys J 39:1471-1475 (2010).
24. Tahiri B, Auzou G, Nicolas JC, Sultan C, Lupo B. Participation of critical residues from the extreme C-terminal end of the human androgen receptor in the ligand binding function. Biochemisty 40:8431-8437 (2001).
25. Gallivan JP, Doherty DA. Cation-p interactions in structural biology. Proc Natl Acad Sci USA 96:9459-9464 (1999) (available at http://capture.caltech.edu).
26. Tina KG, Bhadra R, Srinivasan N. PIC: Protein interactions calculator. Nucleic Acids Res 35:W473-W476 (2007) (available at http://crick.mbu.iisc.ernet.in/~PIC/).
27. Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. Data completeness-the Achilles heel of drug-target networks. Nat Biotechnol 26:983-984 (2008).
28. Mestres J, Martín-Couce L, Gregori-Puigjané E, Cases M, Boyer S. Ligand-based approach to in silico pharmacology: Nuclear receptor profiling. J Chem Inform Model 46:2725-2736 (2006).
29. McGovern SL, Shoichet BK. Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. J Med Chem 46:2895-2907 (2003).
30. Fradera X, Mestres J. Guided docking approaches to structure-based design and screening. Curr Top Med Chem 4:687-700 (2004).
31. Schapira M, Abagyan R, Totrov M. Nuclear hormone receptor targeted virtual screening. J Med Chem 46:3045-3059 (2003).
32. Vogt I, Mestres J. Drug-target networks. Mol Inform 29:10-14 (2010).
33. Cases M, Mestres J. A chemogenomic approach to drug discovery: Focus on cardiovascular diseases. Drug Discov Today 14:479-485 (2009).
34. Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. The topology of drug-target interaction networks: Implicit dependence on drug properties and target families. Mol BioSyst 5:1051-1057 (2009).
35. Vidal D, Garcia-Serna R, Mestres J. Ligand-based approaches to in silico pharmacology. Meth Mol Biol 672:489-502 (2011).
36. Nonell-Canals A, Mestres J. In silico target profiling of one billion molecules. Mol Inform 30:405-409 (2011).
37. Hettne K, Cases M, Boyer S, Mestres J. Connecting small molecules to nuclear receptor pathways. Curr Top Med Chem 7:1530-1536 (2007).